Pharsight

Prolensa patents expiration

PROLENSA's oppositions filed in EPO
PROLENSA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129431 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Sep, 2025

(1 year, 11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144609 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(3 months from now)

US8669290 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(3 months from now)

US8927606 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(3 months from now)

US9561277 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(3 months from now)

US8754131 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(3 months from now)

US8871813 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(3 months from now)

US10085958 BAUSCH AND LOMB Bromfenac bioavailability
Nov, 2032

(9 years from now)

US9517220 BAUSCH AND LOMB Bromfenac bioavailability
Nov, 2033

(10 years from now)

Prolensa is owned by Bausch And Lomb.

Prolensa contains Bromfenac Sodium.

Prolensa has a total of 9 drug patents out of which 0 drug patents have expired.

Prolensa was authorised for market use on 05 April, 2013.

Prolensa is available in solution/drops;ophthalmic dosage forms.

Prolensa can be used as method of treating ocular inflammation; method of treatment to alleviate inflammation of the eye; method of treating ocular inflammation, treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

The generics of Prolensa are possible to be released after 11 November, 2033.

Drugs and Companies using BROMFENAC SODIUM ingredient

Market Authorisation Date: 05 April, 2013

Treatment: Method of treating ocular inflammation; Method of treatment to alleviate inflammation of the eye; Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone ca...

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of PROLENSA before it's drug patent expiration?
More Information on Dosage

PROLENSA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic